This website is intended for healthcare professionals only.
NEW EVIDENCE ON 3L mGC, APPLIED TO DAILY PRACTICE
Prof. Sylvie Lorenzen
Leader of the Phase I Unit at
University Hospital rechts der
Isar, Technical University of
Munich, Germany
Prof. Aziz Zaanan
MD, PhD
Department of Gastroenterology and Digestive Oncology
Georges Pompidou European Hospital, Paris, France
This webinar presents the different treatment options from 1L to 3L metastatic gastric cancer (mGC), with a focus on 3L. It highlights the main therapeutic objectives in 3L and details TAGS clinical trials, showing the benefits of FTD/TPI in OS, PFS, and ECOG PS in 3L and beyond. An interactive clinical case discusses treatment strategy and selection in 3L and 4L.
Key points covered
This webinar highlighted the objectives of mGC treatments in 3L and the advantages of FTD/TPI in terms of efficacy, safety, and quality of life.
In mGC, sequential treatment strategy is a goal
FTD/TPI is the only approved and preferred 3L treatment, providing clinically relevant OS improvement and prolongation of median time to deterioration to ECOG PS
FTD/TPI offers the possibility to benefit from treatments beyond 3L
Webinar Replay
Featured Speakers
Professor Sylvie Lorenzen
Prof Lorenzen’s research interests include clinical research in medical oncology, response evaluation in solid tumor therapy and multimodality treatment of gastrointestinal cancer. She is the head of the gastroesophageal working group of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Professor Aziz Zaanan
Prof Zaanan is the chairman of the French Gastrointestinal Oncologist Association, a member of the ESMO “Gastrointestinal tumors” faculty, and an associate editor of Clinics and Research in Hepatology and Gastroenterology. His research focuses on the study of the genetic alterations in digestive tumors and their implications for prognosis and response to treatment.
